Working… Menu
Trial record 50 of 88 for:    "Neuromuscular Disease" | "Norepinephrine"

Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00757679
Recruitment Status : Completed
First Posted : September 23, 2008
Last Update Posted : July 11, 2013
Information provided by (Responsible Party):
Pierre Fabre Medicament

Brief Summary:
Evaluation of the antinociceptive effect of 7 weeks of treatment with milnacipran, compared to placebo, in fibromyalgia out-patients

Condition or disease Intervention/treatment Phase
Fibromyalgia Syndrome Drug: Milnacipran Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 153 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran. An Exploratory Placebo-controlled Clinical Trial in Fibromyalgia Out-patients
Study Start Date : September 2006
Actual Primary Completion Date : September 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fibromyalgia

Arm Intervention/treatment
Experimental: Milnacipran Drug: Milnacipran

Placebo Comparator: Placebo Drug: Placebo

Primary Outcome Measures :
  1. To assess the antinociceptive effect of 7 weeks of treatment with milnacipran, compared to placebo, in fibromyalgia outpatients. [ Time Frame: 7 weeks ]

Secondary Outcome Measures :
  1. The analgesic effect of 7 weeks of treatment with milnacipran, compared to placebo [ Time Frame: 7 weeks ]
  2. The correlation of the antinociceptive and analgesic effects of milnacipran with the cytochrome CYP2D6 and COMT phenotype polymorphism determinations [ Time Frame: 7 weeks ]
  3. The safety/tolerability and compliance of 8 weeks of treatment with milnacipran [ Time Frame: 8 weeks ]
  4. The therapeutic drug monitoring (TDM) and carry out the PK/PD correlations [ Time Frame: 7 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patient with FMS according to the 1990 ACR criteria
  • patient willing to withdraw from CNS-active therapies commonly used for FMS, including anti-depressants, anti-convulsivants, opiates
  • patient willing to discontinue treatment with tender and trigger point injections, joint injections and anesthetics

Exclusion Criteria:

  • severe psychiatric illness
  • current Major Depressive Episode (MDE)
  • significant risk of suicide
  • history of substance abuse
  • epilepsy
  • myocardial infarction in the past 24 months
  • active cardiac disease
  • congestive heart failure
  • prosthetic heart valve
  • haemodynamically significant valvular heart disease
  • known cardiac rhythm anomalies or conduction abnormalities
  • unstable and uncontrolled arterial hypertension or supine arterial blood pressure over 160/90 mmHg
  • pulmonary dysfunction
  • active liver disease
  • renal impairment
  • documented autoimmune disease
  • current systemic infection
  • active cancer, except basal cell carcinoma or current cancer therapy
  • severe sleep apnoea
  • active peptic ulcer or inflammatory bowel disease (except IBS)
  • unstable endocrine disease
  • pregnancy or breastfeeding
  • concomitant use of non selective MAO inhibitors, MAO-A or -B inhibitors, tricyclics, tetracyclics, SSRIs, NARIs, SNRIs, epinephrine, norepinephrine, clonidine and related compounds, long-acting benzodiazepines
  • concomitant use of oral anticoagulants, anticonvulsants, type Ic antiarrythmics, lithium
  • concomitant use of hypericum and SAMe
  • concomitant use of digitalis preparations
  • regular use of centrally-acting muscle relaxants
  • concomitant use of strong analgesics, including tramadol, codeine or opiates
  • any factor known to affect the HPA axis or autonomic function such as cigarette smoking (regularly over 25 cigarettes a day)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00757679

Layout table for location information
Clinical Pharmacology & Toxicology Multidisciplinary Pain Centre
Geneve, Switzerland
Sponsors and Collaborators
Pierre Fabre Medicament
Layout table for investigator information
Principal Investigator: Jules Desmeules, MD Centre Hospitalier HUG Genève - SUISSE

Layout table for additonal information
Responsible Party: Pierre Fabre Medicament Identifier: NCT00757679     History of Changes
Other Study ID Numbers: F02207 GE 205
First Posted: September 23, 2008    Key Record Dates
Last Update Posted: July 11, 2013
Last Verified: July 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuromuscular Diseases
Serotonin and Noradrenaline Reuptake Inhibitors
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Nervous System Diseases
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Analgesics, Non-Narcotic
Antidepressive Agents
Psychotropic Drugs